Loading stock analysis…
Evidence Synthesis
Last synthesized: 25 Aug 2026, 06:04
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
Zydus Life Sciences (ZYDUSLIFE) has seen its Gross Margin accelerate to 72.11%, up from 16.44%.
The company's revenue growth has also been accelerating, moving from to 22% (quarterly cadence). Additionally, its EPS has seen a significant increase, moving from 10.9619 INR to (quarterly cadence). Despite this, the stock's daily volume has been decelerating, moving from 1,483,923 shares to 857,377 shares, and its close price has also been declining, moving from 1,120 INR to .
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 72.11 % | 16.44 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 16.44 % | 15.78 | ▲ |
| REVENUE_GROWTH_YOY | 22 % | -35.9 | ▲ |
| EPS_ACTUAL | 12.758 INR | 10.962 | ▲ |
| EPS_SURPRISE_PERCENT | 0.062 % | 0.011 | ▲ |
| PRICE_CHANGE_PERCENT | -1.446 % | — | - |
| DAILY_VOLUME | 8,57,377 shares | 14,82,923 | ▼ |
| CLOSE_PRICE | 1,103.8 INR | 1,120 | ▼ |
| NEWS_SENTIMENT_SCORE | 0.27 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 7 count | 8 | ▼ |
| TARGET_PRICE_PREMIUM | 8.33 % | — | - |